Bangkok Lab and Cosmetic PCL (BKK:BLC) Debt-to-EBITDA : 1.05 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Bangkok Lab and Cosmetic PCL Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bangkok Lab and Cosmetic PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ฿258 Mil. Bangkok Lab and Cosmetic PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ฿76 Mil. Bangkok Lab and Cosmetic PCL's annualized EBITDA for the quarter that ended in Dec. 2023 was ฿318 Mil. Bangkok Lab and Cosmetic PCL's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 1.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA or its related term are showing as below:

BKK:BLC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.32 Med: 2.43 Max: 4.14
Current: 1.32

During the past 3 years, the highest Debt-to-EBITDA Ratio of Bangkok Lab and Cosmetic PCL was 4.14. The lowest was 1.32. And the median was 2.43.

BKK:BLC's Debt-to-EBITDA is ranked better than
62.67% of 1425 companies
in the Consumer Packaged Goods industry
Industry Median: 2.13 vs BKK:BLC: 1.32

Bangkok Lab and Cosmetic PCL Debt-to-EBITDA Historical Data

The historical data trend for Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bangkok Lab and Cosmetic PCL Debt-to-EBITDA Chart

Bangkok Lab and Cosmetic PCL Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-EBITDA

4.14

2.43

1.32

Bangkok Lab and Cosmetic PCL Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial				1.88	2.25	1.90	1.10	1.05

Competitive Comparison of Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA

For the Household & Personal Products subindustry, Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA falls into.

Bangkok Lab and Cosmetic PCL Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(258.344	+	75.949)	/	253.074
	=	1.32

Bangkok Lab and Cosmetic PCL's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(258.344	+	75.949)	/	317.616
	=	1.05

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Bangkok Lab and Cosmetic PCL (BKK:BLC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Bangkok Lab and Cosmetic PCL Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bangkok Lab and Cosmetic PCL's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Bangkok Lab and Cosmetic PCL (BKK:BLC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Bangkok Lab and Cosmetic PCL (BKK:BLC) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Nong Chae Sao Road, No. 48/1 Moo 5, Nam Phu, Mueang Ratchaburi, Ratchaburi, Bangkok, THA, 70000

Website

https://www.bangkoklab.co.th

Bangkok Lab and Cosmetic PCL are one of Thailand's comprehensive healthcare solutions groups. Its operation covers the complete value chain of the healthcare business. Its product portfolio comprises generic and new generic drugs, herbal medicines, animal medicines, cosmetics, food supplements, and other health products. Its operation ranges from research and development, manufacturing with international standards, sales, and marketing, to distribution to partnering businesses and customers.

Bangkok Lab and Cosmetic PCL (BKK:BLC) Headlines

No Headlines